← All trials
NCT06434025
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 24, 2024
- Primary completion
- May 24, 2026
- Completion date
- Nov 24, 2026
- First posted
- May 30, 2024
- Last posted
- Jun 3, 2024
- Enrollment
- 99
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Federal University of Health Science of Porto AlegreLead sponsor
- Federal University of Health Science of Porto AlegreSponsor investigator
- Federal University of Health Science of Porto AlegreOfficial
- Vifor Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.